Use the hyperlinks, where available to access additional clinical trial information.
A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer
This study will be conducted across two arms; an experimental arm and a standard-of-care arm. In the experimental arm, participants will REGN2810 as a monotherapy. In the standard-of-care arm, participants will receive one of the following types of chemotherapy: Doses of Paclitaxel + cisplatin OR Doses Paclitaxel + carboplatin OR Doses Gemcitabine + cisplatin or Doses Gemcitabine + carboplatin OR Doses Pemetrexed + cisplatin followed by optional pemetrexed maintenance OR Doses Pemetrexed + carboplatin followed by optional pemetrexed maintenance.
Not currently recruiting